Expression and clinical significance of CPS1 in glioblastoma multiforme

Curr Res Transl Med. 2019 Nov;67(4):123-128. doi: 10.1016/j.retram.2019.08.003. Epub 2019 Sep 3.

Abstract

Carbamoyl phosphate synthetase-1 (CPS1), the first rate-limiting mitochondrial enzyme in the urea cycle, regulates proliferation and differentiation during tumor progression. However, the detailed function of CPS1 in glioblastoma Multiforme (GBM) is still unclear. Here, we highlight mechanisms for CPS1 upregulation and the effects of upregulated CPS1 on GBM tumorigenesis. The transcriptome data from several public databases, such as Oncomine and GEPIA, revealed that CPS1 transcriptional level was significantly upregulated in GBM tissues and cells. Moreover, CPS1 was hypomethylated in GBM tissues. The Wanderer database, linked to the Cancer Genome Atlas (TCGA), showed the association between CPS1 expression or its methylation values and the clinicopathological parameters in GBM patients. Our work fully demonstrated that CPS1 expression was upregulated in GBM and this gene could be used as a potential diagnostic and prognosis indicator for GBM.

Keywords: CPS1; Diagnosis; Glioblastoma multiforme; TCGA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / genetics
  • Brain Neoplasms / diagnosis*
  • Brain Neoplasms / genetics*
  • Brain Neoplasms / pathology
  • Carbamoyl-Phosphate Synthase (Ammonia) / genetics*
  • Cell Line, Tumor
  • DNA Methylation
  • Databases, Genetic
  • Gene Expression Profiling
  • Gene Expression Regulation, Enzymologic
  • Gene Expression Regulation, Neoplastic
  • Glioblastoma / diagnosis*
  • Glioblastoma / genetics*
  • Glioblastoma / pathology
  • Humans
  • Microarray Analysis
  • Prognosis
  • Transcriptome / genetics

Substances

  • Biomarkers, Tumor
  • CPS1 protein, human
  • Carbamoyl-Phosphate Synthase (Ammonia)